Related Experiment Video
Updated: Aug 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential
Marie A Bogoyevitch1, Ingrid Boehm, Aaron Oakley
1Cell Signalling Laboratory, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, University of Western Australia, Crawley, WA 6009, Australia. marieb@cyllene.uwa.edu.au
The c-Jun N-terminal protein kinases (JNKs) are crucial in cellular stress responses. Inhibiting JNKs shows promise for treating neurodegenerative diseases, obesity, diabetes, and arthritis.
Area of Science:
- Molecular Biology
- Cell Signaling
- Pharmacology
Background:
- c-Jun N-terminal protein kinases (JNKs) are a subfamily of mitogen-activated protein kinases (MAPKs).
- JNKs are activated by extracellular stresses and phosphorylate the transcription factor c-Jun.
- Gene knockout studies reveal JNK functions in development and stress response.
Purpose of the Study:
- To investigate the functional roles of JNKs through gene knockout models.
- To explore the therapeutic potential of targeting JNKs for various diseases.
- To review the development of JNK inhibitors for therapeutic applications.
Main Methods:
- In vivo gene knockouts of JNK1, JNK2, and JNK3.
- Analysis of JNK function in models of neurotoxicity, obesity, diabetes, and arthritis.
- Review of chemical and peptide-based JNK inhibitors (e.g., CEP-1347, SP600125).
Main Results:
- Combined knockout of JNK1 and JNK2 is embryonic lethal.
- JNK3 knockout protects against glutamate-induced excitotoxicity in adult brains.
- JNK inhibition shows potential in animal models for stroke, Alzheimer's, Parkinson's, obesity, diabetes, and arthritis.
Conclusions:
- JNK3 is a potential therapeutic target for neuroprotection.
- JNK signaling pathways are implicated in metabolic and oncogenic processes.
- Development of specific JNK inhibitors, including allosteric modifiers, is ongoing and promising.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:15Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Related Concept Videos
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
Inhibition of CDK Activity